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Identity 
Other names: HSULF-1, SULF-1 




The sulfation pattern of heparan sulfate chains 
influences signaling events mediated by heparan sulfate 
proteoglycans located on cell surface. SULF1 is an 
endosulfatase able to cleave specific 6-O sulfate groups 
within the heparan chains.  
This action can modulate signaling processes, 
modulating the effects of heparan sulfate by altering 
binding sites for signaling molecules. 
Description 
Size: 5551 bp. 
Transcription 
4 isoforms: 
- Homo sapiens sulfatase 1 (SULF1), transcript variant 
1, mRNA, 5716 bp 
Accession: NM_001128205.1 GI: 189571640 
- Homo sapiens sulfatase 1 (SULF1), transcript variant 
2, mRNA, 5554 bp 
Accession: NM_001128206.1 GI: 189571642 
 
- Homo sapiens sulfatase 1 (SULF1), transcript variant 
3, mRNA, 5710 bp 
Accession: NM_015170.2 GI: 189571635 
- Homo sapiens sulfatase 1 (SULF1), transcript variant 
4, mRNA, 5548 bp 
Accession: NM_001128204.1 GI: 189571637 
Protein 
Note 
Sulfs are sulfatases that edit the sulfation status of 
heparan sulfate proteoglycans on the outside of cells 
and regulate a number of critical signaling pathways.  
The Sulfs are dysregulated in many cancers.  
The Sulfs are synthesized as pre-proproteins.  
The signal sequence is removed and the pro-protein is 
cleaved by a furin-type proteinase.  
Sulfs mature proteins are secreted as well as retained 
on the cell surface. 
Description 
871 amino acids; 101027 Da. 
Expression 
Expressed at highest levels in testis, stomach, skeletal 
muscle, lung, kidney, pancreas, small intestine and 
colon.  




Adapted from Genecards. 
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Localisation 
Sulfs mature proteins are secreted as well as retained 
on the cell surface. 
Function 
The Sulfs are endoglucosamine-6-sulfatases. They 
liberate 6-O-S mainly from trisulfated disaccharide 
units within the S-domains of heparin/HS chains. The 
Sulfs have been shown to modulate the interaction of a 
number of protein ligands with heparin or heparan 
sulfate. 
Homology 




Sulf1 expression was found to be absent or 
significantly downregulated in ovarian cancer resulting 
in highly sulfated heparin sulfate proteoglycans.  
It has been observed that this down-regulation results in 
increased sulfation of heparin sulfate chains and could 
produce the stabilization of ternary receptor complexes, 
leading to an increased in GF signaling, as described 
for heparin-binding epidermal growth factor-like 
growth factor (HB-EGF), fibroblast growth factor 2 
(FGF2) or amphiregulin in ovarian cancer.  
This modulation of GF effects can affect major events 
including proliferation of tumor cells. Epigenetic 
silencing by methylation is associated with ovarian 
cancer cells and primary ovarian cancer tissues lacking 
Sulf1 expression.  
Cisplatin-induced apoptosis of the ovarian cancer cell 
line, OV207, requires Sulf1 activity. 
Breast cancer 
Oncogenesis 
Sulf1 expression was first described to be significantly 
downregulated in breast cancer. Recent analysis using 
microarray data demonstrated a significant 
upregulation of Sulf1 in breast cancer compared to 
normal counterpart.  
It has been observed that this down-regulation results in 
increased sulfation of heparin sulfate chains and could 
produce the stabilization of ternary receptor complexes, 
leading to an increased in growth factors signaling, as 
described for heparin-binding epidermal growth factor-
like growth factor (HB-EGF), fibroblast growth factor 
2 (FGF2) or amphiregulin in breast cancer.  
This modulation of GF effects can affect major events 
including proliferation of tumor cells.  
A marked reduction of the growth of myeloma or 
breast cancer cell lines was observed in severe 
combined immunodeficient mice when injected cell 
lines were transfected with SULF1 cDNA. It was found  
an aberrant hypermethylation of the Sulf1 promoter in 
breast cancer cell lines and patient samples, leading to a 
reduction of Sulf1 expression. 
Hepatocellular carcinoma 
Oncogenesis 
Sulf1 expression was also found to be significantly 
downregulated in hepatocellular carcinoma.  
It has also been observed that this down-regulation 
results in increased sulfation of heparin sulfate chains 
and could produce the stabilization of ternary receptor 
complexes, leading to an increased in growth factors 
signaling.  
Forced expression of SULF1 also significantly delayed 
the growth of hepatocellular carcinoma cell lines 
xenografts in nude mice.  
Sulf1 enhances acetylation of histone H4 by inhibiting 
HDAC, which subsequently decreased hepatocellular 
carcinoma cell tumorogenesis in mouse model. 
Pancreatic cancer 
Oncogenesis 
Hsulf-1-mediated desulphation of HSPGs reduces the 
growth ability of pancreatic cancer cells, but increases 
the basal invasiveness of these cells and 
chemoresistance, suggesting an important role of this 
enzyme in pancreatic cancer progression. Recent 
analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in pancreatic 
adenocarinoma compared to normal counterpart. 
Head and neck squamous cell 
carcinoma 
Oncogenesis 
Sulf1 expression was also found to be significantly 
downregulated in head and neck squamous cell 
carcinoma cell lines.  
It has also been observed that this down-regulation 
results in increased sulfation of heparin sulfate chains 
and could produce the stabilization of ternary receptor 
complexes, leading to an increased in growth factors 
signaling in head and neck squamous cell carcinoma 
cell lines.  
Hepatocyte growth factor (HGF)-mediated motility and 
invasion were attenuated in neck squamous cell 
carcinoma cell lines displaying an overexpression of 
this sulfatase.  
However, recent analysis using microarray data 
demonstrated a significant upregulation of Sulf1 in 




Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in leukemia compared 
to normal counterpart. 
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Gastric cancer 
Oncogenesis 
Promoter hypermethylation is correlated with the 
HSulf-1 silencing in gastric cancer.  
The restoration of the expression of HSulf-1 inhibited 
cell proliferation, motility, and invasion of the MKN28 
cell line in vitro, as well as in a xenograft mouse 
model.  
No noticeable changes in proliferation and motility 
were observed following restoration of HSulf-1 in 
another gastric cancer cell line AGS.  
HSulf-1 function as a negative regulator of 
proliferation and invasion in MKN28 gastric cancer 
cell line by suppressing Wnt/β-catenin signaling. 
However, as for others cancers, recent analysis using 
microarray data demonstrated a significant 




Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in colon cancer 
compared to normal counterpart. 
Adrenal cancer 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in adrenal cancer 
compared to normal counterpart. 
Esophageal cancer 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in esophageal cancer 
compared to normal counterpart. 
Lung cancer 
Prognosis 
In a cohort of 127 patients with lung adenocarcinoma, 
it was described that high expression of Sulf1 is 
associated with a bad prognosis compared to patients 
with low Sulf1 expression. 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in esophageal cancer 
compared to normal counterpart. 
Mesothelioma 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in mesothelioma 
compared to normal counterpart.  
Furthermore, a review of transcriptome studies 
identified Sulf1 as a mesothelioma gene that could 





Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in renal carcinoma 
compared to normal counterpart. 
Sarcoma 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in sarcoma compared 
to normal counterpart. 
Melanoma 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in cutaneous 
melanoma compared to normal skin. 
Testicular cancer 
Oncogenesis 
Recent analysis using microarray data demonstrated a 
significant upregulation of Sulf1 in testicular cancer 
compared to normal counterpart. 
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